Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1, work by preventing the immune checkpoint molecule from being activated, enabling T cells to proliferate and thereby attack the tumor cells. This evidence concerns the gene CD274 and neoplasm.